An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion  by Speidl, Walter Stefan et al.
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PAtherothrombosis
n Increase of C-Reactive
rotein Is Associated With Enhanced
ctivation of Endogenous Fibrinolysis
t Baseline But an Impaired Endothelial
ibrinolytic Response After Venous Occlusion
alter Stefan Speidl, MD,* Andrea Zeiner, MD,† Mariam Nikfardjam, MD,* Alexander Geppert, MD,‡
elli Jordanova, MD,‡ Alexander Niessner, MD,* Gerlinde Zorn, BSC,* Gerald Maurer, MD, FACC,*
olfgang Schreiber, MD,† Johann Wojta, PHD,* Kurt Huber, MD, FACC‡
ienna, Austria
OBJECTIVES The goal of this study was to determine whether chronic inflammation of the vascular
wall may be associated with an impaired activation of the fibrinolytic system.
BACKGROUND Inflammation plays an important role in the initiation and progression of atherosclerosis, and
the fibrinolytic system may prevent local thrombus formation.
METHODS We included 50 patients six months after their first myocardial infarction. Plasma levels of the
inflammatory marker C-reactive protein (CRP) were determined at basal conditions, and the
fibrinolytic parameters tissue-type plasminogen activator (t-PA) and plasminogen activator
inhibitor type-1 (PAI-1) were measured at basal conditions and after a standardized venous
occlusion (VO) of the forearm.
RESULTS Patients with high CRP levels (3 mg/l) showed a significantly higher t-PA activity at
baseline compared with patients with medium (1 to 2.9 mg/l) and low (1 mg/l) CRP levels
(p  0.005). In contrast, patients with low CRP levels showed a higher increase of t-PA
activity (p  0.05) and a higher reduction of PAI-1 activity during VO (p  0.05) compared
with patients with medium and high CRP levels. A multivariate analysis that included
cardiovascular risk factors and medical treatment showed that CRP is an independent
predictor of the t-PA response after a standardized VO.
CONCLUSIONS Chronic low-grade inflammation is associated with enhanced activation of endogenous
fibrinolysis at baseline but a reduced fibrinolytic response to VO. This impaired endogenous
fibrinolytic capacity might be an important contributor to the increased coronary event rate
associated with elevated CRP levels. (J Am Coll Cardiol 2005;45:30–4) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.09.052American College of Cardiology Foundation
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fnflammation within the vascular wall plays an important
ole in the pathogenesis of atherosclerosis (1). Recent
tudies have shown that elevation of proinflammatory cyto-
ines like tumor necrosis factor (TNF)-alpha (2), soluble
dhesion molecules (e.g., soluble intercellular cell adhesion
olecule-1 [sICAM-1]) (3), as well as systemic inflamma-
ory markers like the acute phase component C-reactive
rotein (CRP) (4,5) are associated with an unfavorable
rogression of disease and an increased risk for acute
ardiovascular events. Thrombus formation after erosion or
upture of coronary plaques is the generally accepted cause
f acute coronary syndromes including ST-segment eleva-
ion myocardial infarction (STEMI). Activation of the
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Manuscript received May 25, 2004; revised manuscript received September 20,
004, accepted September 21, 2004.ndogenous fibrinolytic system is a function of endothelial
ells and a counterpart of local thrombus formation. It has
een shown that inflammatory cytokines are able to induce
rocoagulant and antifibrinolytic activities in vascular cells
6,7). Venous occlusion (VO) of the forearm is a stimulator
or the fibrinolytic system. The normal response to VO is an
ncrease of tissue-type plasminogen activator (t-PA) and a
oncomitant decrease of plasminogen activator inhibitor
ype-1 (PAI-1) activity. This response of the fibrinolytic
ystem to VO has been shown to be impaired in patients
ith atherothrombotic diseases (8). Acute systemic inflam-
ation enhances the endothelial release of t-PA (9), but a
elationship of chronic inflammation and endothelial fi-
rinolytic response has not been demonstrated so far.
herefore, we investigated a possible association between
urrogate markers for chronic inflammation (e.g., plasma
evels of CRP, sICAM, or TNF-alpha) and the fibrinolytic
esponse of the vessel wall on a standardized VO test of the
orearm in patients with proven stable coronary artery
isease.
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atients. We investigated 50 consecutive and clinically stable
atients six months after they had been hospitalized for a first
TEMI. Patients with accompanying diseases that are known
o influence CRP-plasma levels were excluded (10). All pa-
ients gave their informed consent to participate in the trial that
as approved by the local ethics committee and carried out
ccording to the principles of the Declaration of Helsinki.
lood sampling and VO. Blood for basal determination was
rawn from an antecubital vein without or with only minimal
O at resting conditions. A standardized VO test of 15 min
uration was performed on the contralateral forearm (11,12).
aboratory analysis. Plasma levels of CRP were deter-
ined by use of a highly sensitive immunonephelometric
ssay (Dade Behring, Deerfield, Illinois). Plasma levels of
ICAM (Bender MedSystems, Vienna, Austria), TNF-
lpha (eBioscience, San Diego, California), prothrombin
ragment F12 (Dade Behring), t-PA/PAI-1 complexes,
nd PAI-1 antigen (Technoclone, Vienna, Austria) were
easured by specific ELISAs. Tissue-type plasminogen
ctivator antigen and t-PA activity plasma levels were
able 1. Characteristics of the Study Participants—Inflammatory
Total
Low
(CRP <
50
RP (mg/l) 1.36 (0.51–3.13) 0.42 (0
ge (yrs) 55.4 12.2 55.9
ale gender (%) 90.0 9
moker (%) 50.0 5
ystolic blood pressure (mm Hg) 124.8  19.6 127.0
iastolic blood pressure (mm Hg) 79.2 8.4 79.4
ody mass index (kg/m2) 26.9  4.0 25.7
otal cholesterol (mg/dl) 187.0  26.3 182.2
DL cholesterol (mg/dl) 114.6  25.1 110.9
DL cholesterol (mg/dl) 45.8  10.2 48.6
riglycerides (mg/dl) 137.5  75.9 114.5
eak creatine kinase (U/l) 900.1  848.2 847.2
iabetes (%) 20.0 1
amily history of CAD (%) 42.0 5
tatins (%) 54.0 6
eta-blockers (%) 66.0 6
NF-alpha (ng/ml) 6.0 (5.0–9.4) 7.8 (5
ICAM (ng/ml) 75.8 (60.65–88.95) 66.9 (5
12 (nmol/l) 0.85 (0.70–1.20) 0.80 (0
alues are mean SD, median (interquartile range), or percentage. Statistical differen
ere treated with aspirin and angiotensin-converting enzyme inhibitors or angiotens
Abbreviations and Acronyms
CRP  C-reactive protein
F12  prothrombin fragment F12
PAI-1  plasminogen activator inhibitor type-1
sICAM-1  soluble intercellular cell adhesion molecule-1
STEMI  ST-segment elevation myocardial infarction
TNF  tumor necrosis factor
t-PA  tissue-type plasminogen activator
VO  venous occlusionCAD  coronary artery disease; CRP  C-reactive protein; F12  prothrombin fra
ICAM  soluble intercellular cell adhesion molecule; TNF  tumor necrosis factor.etermined by a combined assay system (Technoclone);
AI-1 activity was measured by the Coatest PAI method
Chromogenix, Milano, Italy). Plasma concentration of
brinolytic parameters after VO were corrected for
emoconcentration by use of the correction factor K (1
ematocrit after VO)/(1  hematocrit before VO) (13). All
eterminations were performed in duplicate.
tatistical analysis. Data are represented as median values
nd interquartile range or as mean values  SD. The
ignificance of any differences in proportions was tested by
sing the chi-square test. Statistical differences between
roups in continuous variables were determined by analysis
f variance or, if the Kolmogorov-Smirnov test for deviation
rom normal distribution was significant, by the Kruskal-
allis test. In either case, post-hoc pairwise comparisons
ere done according to the Bonferroni-Holm method (14).
tatistical differences before and after VO were determined
y the Wilcoxon signed rank test for paired samples.
pearman’s correlation was used to compare inflammatory
arkers with VO-induced response of t-PA activity. Mul-
ivariate analysis was performed with the linear regression
odel after log-transformation of t-PA activity. All p values
ere two-tailed, values lower than 0.05 were considered
tatistically significant, and confidence intervals were calcu-
ated at the 95% level. All calculations were performed using
computer program (SPSS for Windows 10.0.1, SPSS Inc.,
hicago, Illinois).
ESULTS
atients with low CRP plasma levels (CRP 1 mg/l),
edium CRP plasma levels (CRP 1 to 2.9 mg/l), and high
Coagulatory Parameters
k
g/l)
Medium Risk
(CRP 1.0–2.9 mg/l)
High Risk
(CRP >3.0 mg/l) p Value
17 13
.59) 2.00 (1.32–2.51) 6.17 (4.66–7.85)
.7 56.8  13.9 52.6  10.9 0.638*
94.1 76.9 0.188
47.1 53.8 0.934
.3 125.0 20.3 121.2  16.7 0.712*
78.8  7.0 79.6  9.5 0.967*
26.5  2.5 29.2  5.7 0.045*
.7 188.5 23.9 192.4  31.8 0.538*
.4 115.1 25.6 119.9  30.5 0.606*
.4 45.3  10.1 42.3  7.6 0.220*
.1 154.8 108.8 150.15 46.3 0.219*
6.5 1,144.18 1,136.0 689.5 679.3 0.342*
29.4 23.1 0.322
29.4 38.5 0.278
52.9 46.2 0.734
76.5 61.5 0.531
.5) 6.0 (5.0–10.4) 6.0 (5.0–7.0) 0.194†
8.7) 71.5 (61.6–85.8) 92.2 (87.2–112.6)  0.001†
.85) 0.9 (0.70–1.70) 1.20 (0.75–1.40) 0.025†
re determined by analysis of variance (*) or by the Kruskal-Wallis test (†). All patients
ptor blockers.and
Ris
1.0 m
20
.29–0
 11
5.0
0.0
 21
 9.2
 3.2
 24
 21
 11
 51
 59
0.0
5.0
0.0
0.0
.3–11
7.0–7
.60–0
ces we
in recegment F12; HDL  high-density lipoprotein; LDL  low-density lipoprotein;
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ifferences in age, blood pressure, and the presence of
ardiovascular risk factors (Table 1). Body mass index was
ignificantly higher in patients with high CRP plasma levels
p  0.05). There was no difference of infarction size as
etermined by peak creatine kinase elevation. Plasma levels
f sICAM were significantly higher in patients with ele-
ated CRP levels, whereas plasma levels of TNF-alpha
howed no statistical difference between the three groups.
atients with elevated CRP plasma levels showed an acti-
ation of coagulation as determined by elevated F12
lasma levels (p  0.025).
The t-PA activity at baseline was significantly higher in
atients with high CRP levels (p  0.005), suggesting a
hronic activation of the fibrinolytic system associated with
ubclinical inflammation of the vessels. Patients with low
RP levels showed significantly lower PAI-1 antigen levels
han patients with elevated CRP levels (p  0.05). During
standardized VO of the forearm, t-PA activity, t-PA
ntigen, and t-PA/PAI-1 complexes increased between 1.7-
nd 1.9-fold (p  0.0001). In contrast, PAI-1 activity and
AI-1 antigen showed a significant decrease (p  0.0001)
Table 2).
The CRP plasma levels showed a significant inverse
orrelation to the VO-induced relative increase of t-PA
ctivity (r0.28, p 0.05) (Fig. 1), whereas TNF-alpha
r  0.21, p  0.16) and sICAM (r  0.18, p  0.21)
ere not significantly associated with the response of t-PA
ctivity during VO.
Table 2 illustrates that the VO-mediated increase in t-PA
ctivity was 2.7-fold (1.9 to 7.6) in patients with CRP levels
0.1 mg/l and significantly higher compared with patients
able 2. Plasma Levels of Fibrinolytic Parameters at Baseline, Af
Total
Low
(CRP <
efore VO
t-PA activity (IU/ml) 0.30 (0.10–0.70) 0.20 (0
t-PA antigen (ng/ml) 5.8 (3.7–7.1) 5.8 (4
PAI-1 activity (IU/ml) 8.3 (2.9–16.3) 5.3 (2
PAI-1 antigen (ng/ml) 108.1 (57.6–193.8) 66.2 (4
t-PA/PAI-1 complexes (ng/ml) 26.9 (18.0–36.6) 22.6 (1
Ratio of t-PA/PAI-1 activity 0.046 (0.012–0.12) 0.044 (0
fter VO
t-PA activity (IU/ml) 0.74 (0.26–2.14) 1.35 (0
t-PA antigen (ng/ml) 11.9 (9.1–18.3) 12.8 (8
PAI-1 activity (IU/ml) 3.5 (0.1–13.3) 0.1 (0
PAI-1 antigen (ng/ml) 67.7 (33.8–156.1) 41.5 (2
t-PA/PAI-1 complexes (ng/ml) 50.4 (30.1–76.4) 36.4 (2
Ratio of t-PA/PAI-1 activity 0.27 (0.025–7.59) 3.65 (0
-fold change
t-PA activity 1.9 (1.4–3.6) 2.7 (1
t-PA antigen 1.9 (1.5–3.0) 2.5 (1
PAI-1 activity 0.62 (0.04–0.86) 0.048 (0
PAI-1 antigen 0.83 (0.64–0.93) 0.84 (0
t-PA/PAI-1 complexes 1.7 (1.3–2.6) 2.0 (1
alues are median (interquartile range). Statistical differences were determined by th
CRP  C-reactive protein; PAI-1  plasminogen activator inhibitor type-1; t-Pith medium CRP levels (1.7-fold increase [1.2 to 3.0]) and
a
digh CRP levels (1.7-fold increase [1.2 to 2.3]) (p  0.05).
oreover, patients with signs of ongoing inflammation
medium and high CRP plasma levels) exhibited a blunted
eduction of PAI-1 activity (p  0.05). Accordingly, the
atio of t-PA/PAI-1 activity after VO tended to be higher
n patients with low CRP-plasma levels (p  0.051). The
hanges of antigen levels were comparable between the
hree groups of patients.
To investigate whether high CRP levels are an indepen-
ent determinant of VO-induced response of t-PA activity,
e performed a multivariate analysis that included CRP
roups, plasma lipids, cardiovascular risk factors, and treat-
ent with statins and beta-blockers as independent vari-
bles. To rule out that the blunted increase of t-PA activity
O, and x-Fold Increase
k
g/l)
Medium Risk
(CRP 1.0–2.9 mg/l)
High Risk
(CRP >3.0 mg/l) p Value
.58) 0.20 (0.10–0.35) 0.80 (0.35–1.50) 0.005
) 5.8 (4.0–8.3) 6.8 (3.8–9.4) 0.679
.1) 8.8 (2.8–22.9) 11.7 (2.1–17.6) 0.588
07.8) 160.1 (118.0–210.1) 101.7 (58.0–206.9) 0.012
0.9) 28.9 (16.8–45.2) 33.3 (19.4–44.0) 0.203
0.19) 0.017 (0.006–0.091) 0.085 (0.028–4.10) 0.199
.25) 0.34 (0.18–0.79) 1.34 (0.53–3.58) 0.015
.7) 12.4 (10.1–15.8) 10.4 (8.8–16.5) 0.564
) 8.3 (1.4–19.1) 8.6 (0.1–16.6) 0.054
6.3) 143.4 (103.5–214.3) 66.5 (40.4–146.2) 0.003
00.1) 55.3 (28.2–84.8) 52.4 (40.9–64.5) 0.679
2.02) 0.054 (0.007–0.49) 0.16 (0.029–2.62) 0.051
) 1.7 (1.2–3.0) 1.7 (1.2–2.3) 0.028
) 1.8 (0.8–2.9) 1.7 (1.1–2.3) 0.167
0.72) 0.69 (0.31–0.87) 0.83 (0.59–0.90) 0.028
.92) 0.88 (0.69–0.96) 0.72 (0.61–0.87) 0.331
) 1.6 (1.1–3.1) 1.6 (1.2–2.2) 0.676
skal-Wallis test.
issue-type plasminogen activator; VO  venous occlusion.
igure 1. Correlation of relative increase of tissue-type plasminogenter V
Ris
1.0 m
.10–0
.0–8.3
.9–14
4.8–1
5.5–3
.006–
.35–2
.1–19
.1–5.6
3.3–6
8.3–1
.29–2
.9–7.6
.5–3.3
.019–
.60–0
.4–2.8ctivator (t-PA) activity with plasma levels of C-reactive protein (CRP)
uring a standardized venous occlusion (VO) test of the forearm.
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s merely due to the increase of baseline t-PA activity, we
lso included t-PA activity at baseline. Table 3 shows that
he only statistically significant determinants for the increase
f t-PA activity during VO were age, hypertension, and
RP levels.
ISCUSSION
e stratified patients with stable CAD, six months after a
rst STEMI, according to their CRP levels, into the
enerally accepted three clinical risk groups, namely patients
ith low CRP levels and low risk for future cardiovascular
vents (CRP 1 mg/l), patients with medium CRP levels
nd moderate risk (1 to 2.9 mg/l), and patients with high
RP plasma levels and high risk for future cardiovascular
vents (CRP 3 mg/l) (15). Patients with high CRP
lasma levels show at baseline a markedly increased activa-
ion of coagulation and fibrinolysis as determined by a
ignificant elevation of F12 and t-PA activity. In contrast,
n acute prothrombotic stimulus is not able to further
ncrease the endothelial release of t-PA activity in patients
ith high (3 mg/l) as well as medium (1 to 2.9 mg/l) CRP
evels. The blunted increase of t-PA activity upon VO was
ot merely due to the increase of baseline t-PA activity as
hown by performing a multivariate analysis that included
-PA activity at baseline. Patients with low CRP levels
howed also a significantly higher consumption of free
AI-1 during VO compared with patients with CRP levels
1 mg/l. A multivariate analysis that included cardiovas-
ular risk factors and medical treatment known to have anti-
r profibrinolytic effects showed that CRP is an indepen-
ent predictor of the t-PA response after a standardized
O. We suggest that a reduced t-PA release consecutively
able 3. Multivariate Analysis of Relative t-PA Response
uring VO, Including Risk Factors, Medical Treatment, and
aseline t-PA Activity
Univariate
p Value Beta p Value
RP 0.016 0.365 0.022
ge  0.001 0.719  0.001
ypertension 0.207 0.409 0.004
ender 0.312 0.027 0.841
moking 0.144 0.005 0.976
ody mass index 0.648 0.286 0.071
otal cholesterol 0.971 0.301 0.725
DL cholesterol 0.274 0.373 0.650
DL cholesterol 0.291 0.004 0.990
riglycerides 0.196 0.222 0.487
iabetes 0.237 0.154 0.226
amily history of CAD 0.575 0.103 0.477
tatins 0.993 0.002 0.986
eta-blockers 0.646 0.071 0.576
aseline t-PA activity 0.140 0.007 0.959
djusted R2 0.407 0.002
bbreviations as in Tables 1 and 2.iminishes the capacity to counteract thrombus formation after rupture or erosion of coronary plaques and thus
ncreases the risk for acute coronary events.
How chronic inflammation may be linked with a dimin-
shed fibrinolytic capacity is still under investigation. Most
tudies have focused on PAI-1 as the fibrinolytic parameter
eing responsible for a reduced fibrinolytic potential. The
roinflammatory cytokines TNF-alpha and interleukin-1
nduce an increase of PAI-1 secretion in vascular cells (6),
nd PAI-1 has been shown to be a part of the acute-phase
esponse induced by proinflammatory cytokines in hepato-
ytes (10). We showed that patients with medium or high
RP plasma levels show significantly higher levels of PAI-1
ntigen at baseline compared with patients with CRP levels
1 mg/l. The CRP plasma levels may reflect, in part, the
resence and severity of atherosclerosis (16), and coronary
laque burden is inversely related with substance-P–induced
-PA release from the coronary artery (17). Accordingly, the
lunted fibrinolytic response as observed in our study may
e related to the extent of atherosclerosis that may be
eflected by plasma levels of CRP.
Plasma levels of the proinflammatory cytokine TNF-
lpha and the soluble adhesion molecule sICAM did not
orrelate with t-PA release upon VO. Although TNF-alpha
ay directly lead to a prothrombotic and hypofibrinolytic
henotype of vascular cells, and sICAM may be a marker
or inflammatory activation of endothelial cells, in our study
either parameter was associated with the fibrinolytic ca-
acity. One may speculate that the acute-phase reactant
RP might show a better correlation to the blunted
brinolytic response upon VO because CRP is a very
ensitive but, in contrast to TNF-alpha and sICAM, non-
pecific marker for inflammatory processes (10).
C-reactive protein may also promote atherogenesis and
hrombosis by perturbing normal endothelial cell function
y inducing tissue factor expression, the production of
roinflammatory cytokines, the expression of adhesion mol-
cules, and the down-regulation of nitric oxide and prosta-
yclin production by endothelial cells (18,19). Taking to-
ether the results of a study showing that CRP induces the
roduction of PAI-1 in endothelial cells (20) and our study,
ne could speculate that CRP may also promote athero-
hrombosis through the reduction of the fibrinolytic poten-
ial by affecting endothelial cells.
We have shown that the endothelial release of t-PA
ctivity upon VO, reflecting the fibrinolytic capacity, is
iminished in patients with medium and high CRP plasma
evels independently from cardiac risk factors and medical
reatment. This could explain, in part, the moderate and
igh risk for acute cardiovascular events in these patients,
nd one could speculate that this impaired endogenous
brinolytic capacity might be an important contributor to
he increased coronary event rate associated with elevated
RP levels. Thus, patients after a first myocardial infarction
ith medium (1 to 2.9 mg/l) and high (3 mg/l) CRP
evels may benefit from intensive antithrombotic treatment
nd treatment with statins or modulators of the renin-
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n plasma lipids or hypertension— have also anti-
nflammatory properties that may improve endogenous
brinolytic capacity.
eprint requests and correspondence: Dr. Kurt Huber, 3rd
epartment of Medicine, Wilhelminenspital, Montlearstr. 37,
-1171 Wien, Austria. E-mail: kurt.huber@meduniwien.ac.at.
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